◼

News

All News

Keep up to date with the world of Septerna

All

2025

2024

2023

2022

05.20.24

Septerna to Present Preclinical Data from GPCR Drug Discovery Engine at ENDO 2024

Native Complex Platform™ has rapidly produced multiple GPCR-targeted programs approaching clinical development Oral, small molecule parathyroid hormone 1 receptor (PTH1R) agonist for hypoparathyroidism preparing to enter Phase 1 trials in late 2024 Oral, thyroid stimulating hormone receptor (TSHR)

02.22.24

Septerna to Participate in Upcoming Investor and Industry Conferences

SOUTH SAN FRANCISCO, Calif. – Feb. 22, 2024 – Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that members of the management team, including Jeffrey Finer, M.D., Ph.D., Chief Executive

02.07.24

Septerna Appoints Industry Veterans Bernard Coulie, M.D., Ph.D., and Shalini Sharp to its Board of Directors

SOUTH SAN FRANCISCO, Calif. – Feb. 6, 2024 – Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced the appointments of Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer of Pliant

09.12.23

Septerna Announces Novel GPCR-targeted Program Acquired by Vertex

Septerna to Receive $47.5 Million Upfront and Additional Potential Future Payments SOUTH SAN FRANCISCO, Calif., Sept. 12, 2023 – Septerna , a biotechnology company discovering and advancing novel oral small molecule medicines targeting G protein-coupled receptors (GPCRs), today

08.31.23

Septerna Bolsters Leadership Team as the Company Advances its Multi-Product Pipeline Toward Clinical Studies

David Martin, Ph.D., joins as Senior Vice President of Development Sciences Samira Shaikhly joins as Chief People Officer SOUTH SAN FRANCISCO, Calif. – August 31, 2023 – Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled

07.11.23

Septerna Secures $150 Million in Series B Financing to Advance Pipeline of Novel GPCR-targeted Medicines

Financing led by RA Capital Management with significant support from world-class group of existing and new investors Proceeds from financing to support development of lead program targeting PTH1R through clinical proof-of-mechanism Pipeline of multiple programs and proprietary GPCR Native Complex™

12.19.22

Septerna Announces the Formation of a Cross-Functional Scientific and Drug Discovery Advisory Board

Advisory board brings world-renowned expertise in GPCR biology and technology, and drug discovery to Septerna SOUTH SAN FRANCISCO, Calif. – December 19, 2022 – Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs),

09.22.22

Septerna Appoints Jeffrey Finer, MD, PhD, as Chief Executive Officer

SOUTH SAN FRANCISCO, Calif. – September 22, 2022 – Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors (GPCRs), today announced that Jeffrey Finer, MD, PhD, has been named the company’s full-time Chief Executive Officer,

07.28.22

Septerna Strengthens Leadership Team to Advance Novel Small Molecule GPCR Medicines

Liz Bhatt, MS, MBA, joins as Chief Operating Officer Ran Xiao joins as Vice President of Finance and Business Operations SOUTH SAN FRANCISCO, Calif. – July 28, 2022 – Septerna, a biotechnology company discovering and advancing novel small molecule medicines targeting G protein-coupled receptors

01.27.22

Septerna Launches with $100 Million Series A Financing to Expand the Frontier of GPCR-targeted Medicines using the Native Complex™ Platform

Septerna’s proprietary technology recapitulates GPCRs with their native structure, function and dynamics for unprecedented drug discovery for many diseases Founded by preeminent scientific leaders in the biology and structure of G protein-coupled receptors (GPCRs) Financing led by Third Rock

First page
Previous page
Page 1
Current page 2

Displaying 11 - 20 of 20

News

All News

Pioneering a New Era of GPCR Drug Discovery